Geng M - Search Results

1

Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).

Li L, Liu F, Jin N, Tang S, Chen Z, Yang X, Ding J, Geng M, Jiang L, Huang M, Cao J. Li L, et al. Among authors: geng m. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2600-4. doi: 10.1016/j.bmcl.2016.04.029. Epub 2016 Apr 12. Bioorg Med Chem Lett. 2016. PMID: 27106711

2

Studies of marine sulfated polymannuroguluronate on endothelial cell proliferation and endothelial immunity and related mechanisms.

Wang L, Geng M, Li J, Guan H, Ding J. Wang L, et al. Among authors: geng m. J Pharmacol Sci. 2003 Aug;92(4):367-73. doi: 10.1254/jphs.92.367. J Pharmacol Sci. 2003. PMID: 12939521 Free article.

3

Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms.

Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, Ding J, Geng M. Fan Y, et al. Among authors: geng m. Neurosci Lett. 2005 Feb 21;374(3):222-6. doi: 10.1016/j.neulet.2004.10.063. Epub 2004 Dec 10. Neurosci Lett. 2005. PMID: 15663967

4

Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin.

Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F, Shen X, Tong LJ, Li MH, Zhang C, Li WH, Lin LP, Ding J. Tong YG, et al. Mol Pharmacol. 2006 Apr;69(4):1226-33. doi: 10.1124/mol.105.020537. Epub 2006 Jan 19. Mol Pharmacol. 2006. PMID: 16424078

5

Emerging cancer therapeutic opportunities target DNA-repair systems.

Ding J, Miao ZH, Meng LH, Geng MY. Ding J, et al. Trends Pharmacol Sci. 2006 Jun;27(6):338-44. doi: 10.1016/j.tips.2006.04.007. Epub 2006 May 11. Trends Pharmacol Sci. 2006. PMID: 16697054 Review.

6

Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.

Hu CX, Zuo ZL, Xiong B, Ma JG, Geng MY, Lin LP, Jiang HL, Ding J. Hu CX, et al. Mol Pharmacol. 2006 Nov;70(5):1593-601. doi: 10.1124/mol.106.027714. Epub 2006 Aug 16. Mol Pharmacol. 2006. PMID: 16914642

7

Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.

Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, Zhang Z, Zhang X, Xie C, Geng M, Ding J. Zhao H, et al. Among authors: geng m. Cancer Res. 2006 Sep 1;66(17):8779-87. doi: 10.1158/0008-5472.CAN-06-1382. Cancer Res. 2006. PMID: 16951194

8

R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.

Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, Geng MY, Cai YJ, Ding J. Zhu H, et al. Among authors: geng my. Mol Cancer Ther. 2007 Feb;6(2):484-95. doi: 10.1158/1535-7163.MCT-06-0584. Mol Cancer Ther. 2007. PMID: 17308047

9

Philinopside E, a new sulfated saponin from sea cucumber, blocks the interaction between kinase insert domain-containing receptor (KDR) and alphavbeta3 integrin via binding to the extracellular domain of KDR.

Tian F, Zhu CH, Zhang XW, Xie X, Xin XL, Yi YH, Lin LP, Geng MY, Ding J. Tian F, et al. Mol Pharmacol. 2007 Sep;72(3):545-52. doi: 10.1124/mol.107.036350. Epub 2007 Jun 12. Mol Pharmacol. 2007. PMID: 17565003

10

MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison.

Xie CY, Zhu H, Lin LP, Miao ZH, Geng MY, Cai YJ, Chen Y, Zhao HJ, Luo HB, Zhang XW, Fan LM, Shen YM, Ding J. Xie CY, et al. Mol Cancer Ther. 2007 Nov;6(11):3059-70. doi: 10.1158/1535-7163.MCT-07-0014. Mol Cancer Ther. 2007. PMID: 18025289

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

980 results

Search Page

Filters